Internet-based cognitive behavioural self-help for premenstrual syndrome: study protocol for a randomised controlled trial by Johanna N Kues et al.
TRIALS
Kues et al. Trials 2014, 15:472
http://www.trialsjournal.com/content/15/1/472STUDY PROTOCOL Open AccessInternet-based cognitive behavioural self-help for
premenstrual syndrome: study protocol for a
randomised controlled trial
Johanna N Kues1*, Carolyn Janda1, Maria Kleinstäuber1 and Cornelia Weise1,2Abstract
Background: With a prevalence of 3 to 8% among women of reproductive age, severe premenstrual symptoms are
very common. Symptoms range from emotional and cognitive to physical changes. Severe symptoms (that is,
premenstrual syndrome) can have a strong impact on everyday functioning and quality of life. Impairment can be
as serious as that of dysthymic disorders. Many affected women receive either no treatment at all or are unsatisfied
with their treatment. Although there is some evidence for the reduction of distress through cognitive behavioural
therapy, there are only a small number of randomised controlled trials carefully investigating the efficacy of this
psychotherapeutic approach. Thus, this study aims to evaluate the efficacy of a cognitive behavioural self-help
treatment for women suffering from premenstrual syndrome.
Methods/design: The study is conducted as a randomised controlled trial. The complex diagnostic assessment
includes the completion of a symptom diary over two consecutive cycles and a telephone interview. Eligible
women are randomly assigned to either a treatment or a wait-list control group. The intervention is based on
cognitive behavioural therapy principles and is provided via the internet. It consists of 14 different modules on
which participants work over 8 consecutive weeks. In addition to written information, participants receive email
feedback from a clinical psychologist on a weekly basis. Participants assigned to the wait-list receive the treatment
after the end of the waiting period (8 weeks). The primary outcome measure is the Premenstrual Syndrome Impairment
Measure. Secondary outcomes include the Premenstrual Syndrome Coping Measure, the Short-Form Social Support
Questionnaire, the Questionnaire for the Assessment of Relationship Quality, and the Perceived Stress Scale. Data is
collected during the premenstrual (luteal) phase at pre-treatment, post-treatment, and 6-month follow-up.
Discussion: So far, there is no study investigating internet-based cognitive behavioural therapy for premenstrual
syndrome. The programme approaches the problem of high prevalence in combination with severe impairment and
insufficient treatment options.
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Keywords: Premenstrual syndrome, Premenstrual dysphoric disorder, Internet-based cognitive behavioural therapy,
Study protocol* Correspondence: kuesj@uni-marburg.de
1Department of Psychology, Division of Clinical Psychology and
Psychotherapy, Philipps-University of Marburg, Gutenbergstr. 18, 35032
Marburg, Germany
Full list of author information is available at the end of the article
© 2014 Kues et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kues et al. Trials 2014, 15:472 Page 2 of 9
http://www.trialsjournal.com/content/15/1/472Background
A large proportion of women of reproductive age suffer
from premenstrual symptoms. Some of the typical and
frequently reported premenstrual complaints are phys-
ical discomfort, affect lability, anxiety, depressed mood,
fatigability, hopelessness, and irritability [1]. The symp-
toms can lead to severe impairment at work, in social
activities, or relationships [2]. The marital relationship is
often impaired most intensely in comparison to other
social relationships and activities outside the home [3,4].
Quality of life is lowered to a degree comparable to that
of dysthymic disorders [3] and suicidal tendency is in-
creased [1].
According to the impairment caused by the symptoms,
premenstrual syndrome (PMS) can be distinguished from
a more severe form, the premenstrual dysphoric disorder
(PMDD). PMDD is associated with a higher number,
severity, duration, and quality of symptoms [5]. Conse-
quently, PMS and PMDD can be arranged on a con-
tinuum. The central feature of both disorders is the cyclic
pattern of symptoms: the symptoms arise during the final
premenstrual phase and diminish with or a few days after
the beginning of menses.
Only PMDD represents a clinical, diagnostic entity. In
the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition text revision (DSM-IV-TR), PMDD
was only included in the appendix at a research criterion
stage [6]. Since DSM-5 [7] PMDD has been outlined as
a distinct diagnostic category. (Wording of PMDD cri-
teria in this text is simplified and abbreviated. For exact
wording, please consult the DSM-5 manual [7]). To
diagnose PMDD, at least five symptoms out of eleven
(including at least one out of the first four affective
symptoms) have to be confirmed by prospective daily
self-ratings of PMS symptoms in the form of a diary over
two consecutive menstrual cycles [7]. These symptoms
include: (1) affective lability; (2) irritability or anger or
increased interpersonal conflicts; (3) depressed mood;
(4) anxiety or tension; (5) decreased interest; (6) diffi-
culty in concentrating; (7) lethargy, fatigability, or lack of
energy; (8) change in appetite; (9) hypersomnia or in-
somnia; (10) a sense of being overwhelmed or out of
control; and (11) other physical symptoms (for example,
breast tenderness, pain). The symptoms have to exist in
the majority of cycles over the preceding 12 months and
must cause significant distress or interference. Symp-
toms are not an exacerbation of the symptoms of an-
other mental disorder; however, other mental disorders
may co-occur. With the inclusion of PMDD in the
DSM-5, some changes have been implemented [8]: “dis-
tress” in addition to interference, a more precise timing
of the onset and the offset of the premenstrual symptoms,
possibility of co-occurrence of other mental disorders,
possibility of a provisional diagnosis based on clinicalhistory, and distinctiveness from substance use or another
medical condition. In particular, the possibility of a
provisional diagnosis is an important change as it allows
an earlier diagnosis and thus earlier access to healthcare
for suffering women [9]. Also the extension of the interfer-
ence criteria with the expression of distress is essential as
it takes into account that women may maintain their func-
tion with a high level of distress without suffering from
interference in functioning [10].
As already mentioned, PMS does not represent a dis-
tinct clinical entity and the distinction between PMS and
PMDD remains unclear [11]. The American Congress of
Obstetricians and Gynecologists (ACOG) [5] suggests
some diagnostic criteria for PMS that require only one
symptom out of a list of ten affective and somatic symp-
toms [5]. They seem to focus more on the impairment and
distress than on a specified number of symptoms [3,10].
The prevalence of PMS and PMDD differs not only
due to differences in severity but also due to differences
in methodology and diagnostic criteria [3]. About 75% of
women of reproductive age report at least one premen-
strual symptom [1]; 18% of women of reproductive age
suffer from PMS [1]. Prevalence for PMDD based on the
DSM-IV-TR ranges from 3 to 8% [10], with a 12-month
prevalence of 5.3% [1].
About 85% of women with PMS are considerably im-
paired and seek treatment [12], but only 20% receive
some kind of psychological treatment [1]. The direct
costs for the healthcare system and especially the indir-
ect costs through the loss of work productivity are strik-
ing [3,13]: having PMS is associated with an annual
increase of $59 in direct and up to $4,333 in indirect
costs per patient [13].
Consequently, given the high prevalence and the nega-
tive impact on functioning, effective treatment is needed.
Common treatments are pharmacotherapy (for example,
antidepressants, anxiolytics, cycle-modifying hormonal
agents), lifestyle changes (for example, exercise, dietary
recommendations, relaxation therapy), complementary
therapies such as nutritional supplements (for example,
vitamin D, calcium, magnesium) and natural products
(for example, St John’s wort extract, vitex agnus castus
extract, evening primrose oil), and cognitive behavioural
therapy (CBT) [14-16].
The Royal College of Obstetricians and Gynaecologists
(RCOG) suggests a special treatment regimen for the
management of severe PMS which is introduced in the
following section [17]. Although complementary therap-
ies have grown in popularity [18] there is no compelling
evidence for their use [17,19]. For lifestyle changes, suffi-
cient randomised controlled trials (RCTs) are lacking as
well [16,17]. Nevertheless, some evidence exists for life-
style changes (for example, exercise [20], dietary recom-
mendations [21], relaxation therapy [22]) as well as for
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cium [23], magnesium [24]), and natural products (agnus
castus extract [25]). Both complementary therapy (vitamin
B6) and lifestyle changes (exercise) are recommended by
the RCOG [17].
Common cycle-modifying hormonal agents that are
used in the treatment of PMS/PMDD are the combined
oral contraceptive pill, oestrogen, progesterone, and
gonadotrophin-releasing hormone (GnRH). Evidence for
the administration of progesterone [26] as well as for the
use of second-generation combined oral contraceptives
is lacking; in particular, RCTs are rare [14]. By contrast,
the administration of oestrogen via oestradiol patches or
implants [27] as well as the use of GnRH has proven
effective [28]. However, the named hormonal therapies
are associated with severe side effects [14,29] which
sometimes resemble or intensify premenstrual symptoms
[14]. Regardless, the use of a new combined pill includ-
ing progestin which has not been derived from testoster-
one (Yasmin®, Bayer Health Care, Leverkusen, Germany)
is promising and its application is thus recommended by
the RCOG [17].
Furthermore, selective serotonin re-uptake inhibitors
(SSRIs) are recommended as one of the first-line pharma-
cological management options [17]. Four meta-analyses
support the efficacy of SSRIs [30-33]. However, side effects
of SSRI treatment [30,34] lead to high rates of withdrawal
from treatment. Further problems are the high placebo
reaction in patients suffering from PMS [35] and the low
responder rate of 40% [32].
Because of the problems of pharmacotherapy, CBT
has been suggested as an additional treatment approach
[36,37] and has even been named a routine treatment
option in the guidelines of the RCOG [17]. Theoretical
substantiation for the adoption of CBT for PMS/PMDD
comes from the cognitive model for PMS by Blake and
colleagues [38]. The model emphasizes the importance
of cognitive appraisal of the premenstrual symptoms and
the associated distress. Here, CBT can intervene by
questioning the attributions and by teaching coping
skills. In addition, CBT has been shown to be effective
for disorders sharing common symptoms with PMS/
PMDD (for example, affective and somatic symptom dis-
order) [39]. Some studies showed promising results for
CBT interventions for PMS/PMDD. In a meta-analysis
examining CBT for PMS, nine studies were included
[36]. The authors found medium effect sizes for redu-
cing anxiety and depression. Another meta-analysis,
containing 22 studies, revealed small to medium effects
for CBT and serotonergic antidepressants concerning
different outcomes (for example, mood and functional
impairment) [40]. To date, only a small number of well
designed RCTs have investigated the efficacy of CBT for
PMS [36,39]. Methodological limitations are, for instance,a lack of description of the randomization and treatment
procedure, substantial loss to follow-up, and potential
reporting bias. Besides, they show partially contradicting
findings with unsatisfactory [40] or lacking evidence [39]
contrasting findings of significant improvement [36].
Thus, one aim of the current study is to develop a well-
designed, CBT-oriented self-help programme and to
examine its efficacy for distress reduction in PMS patients.
The high percentage of women being dissatisfied with
their actual treatment [41] reveals the importance of
new approaches for treating PMS. Our treatment is con-
ducted as an internet-based programme. This decision
was reached for the following reasons. First, an internet-
based approach enables us to provide treatment for a
greater number of women and can therefore reduce
waiting time for patients [42]. Second, stigma associated
with seeing a psychologist and conveying sensitive infor-
mation to a person can be reduced [42,43]. This advan-
tage seems to be particularly important because of
taboos and stigmata linked with the topics of menstru-
ation and PMS [44,45], the women’s fear and experience
of not being taken seriously [38,41,46], and their mainly
medically oriented perception of PMS [38]. Positive ef-
fects of internet-based CBT (iCBT) in reducing impair-
ment or symptom severity have been found for several
functional syndromes or psychosomatic disorders (for
example, pain, headache [47], or tinnitus [48]) as well as
for depression [49]. Hence, it is highly probable that an
iCBT programme can equally well target the somatic
symptoms and the affective symptoms that go along
with PMS/PMDD.
This study aims to evaluate the efficacy of an iCBT
self-help programme for reducing mental and functional
impairment in women suffering from severe PMS or
from PMDD and improving their coping strategies. First,
we hypothesize that the treatment group receiving the
iCBT will show a lower impairment than the wait-list
control group. Second, we hypothesize that the treat-
ment group improves its coping strategies in comparison
to the wait-list control group.Method
Study design and population
This study will be implemented as an RCT including an
experimental group and a wait-list control group. The
study is approved by the Ethics Committee at the Depart-
ment of Psychology of the Philipps University Marburg
(2013–09) and was registered under clinicaltrials.gov
(NCT01961479). Prior to participation in the research,
informed consent was obtained.
Eligible women are between 18 and 45 years of age.
They are required to have sufficient knowledge of German
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Figure 1 Study process. t = measurement points: t0 = screening for
basic inclusion criteria. t1 = first assessment of primary and
secondary outcome in luteal phase, first and second cycle of the
symptom diary. t2 = second assessment in luteal phase, third and
fourth cycle of the symptom diary, approximately 2 months after
admission. t3 = for the wait-list group only, third assessment of primary
and secondary outcome in luteal phase, fifth and sixth cycle of the
symptom diary, approximately 6 months after admission. t4 = for the
treatment group: third assessment of primary and secondary outcome
in luteal phase, approximately 10 months after admission; for the
wait-list group: fourth assessment of primary and secondary outcome
in luteal phase, approximately 14 months after admission.
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as outlined in the guidelines of the ACOG [5].
Exclusion criteria for the study are as follows:
1) Diagnosis of a psychosis or a bipolar disorder
2) Diagnosis of an eating disorder
3) Diagnosis of moderate or severe depression
4) Diagnosis of somatic symptom disorder
5) Participation in psychotherapy due to premenstrual
symptoms (currently or in the past)
6) Acute suicidal tendencies
7) Birth of a child or lactation during the last 3 months
8) Pregnancy
9) Gynaecological diseases (hysterectomy,
oophorectomy, gynaecological cancer, polycystic
ovary syndrome, endometriosis, infertility)
10) Begin or change in taking of antidepressants,
benzodiazepines/antipsychotics, combined oral
contraceptives, or hormones during the last
3 months
Sample size and power calculations
Effect sizes of the difference between an iCBT programme
for PMS and a wait-list control group cannot be estimated
precisely because the combination of these two ap-
proaches – CBT and internet-based interventions – for
treating PMS has not yet been evaluated systematically.
First, there is currently no internet-based self-help
programme for PMS. However, iCBT has been found to
be effective for disorders sharing common symptoms
with PMDD (for example, affective and somatic disor-
ders) [39]. Large effects for internet-based treatments
with psychologist support for depression and anxiety
disorders compared to control conditions were found in
a meta-analysis [49]. The effects found for internet-
delivered treatments aimed at health problems (pain and
headache) were comparable to the effects for face-to-
face interventions [47].
Second, CBT face-to-face programmes for PMS are
not well evaluated and suffer from a limited methodo-
logical quality as well [36,39]. In one meta-analysis
examining CBT for PMS [36] the authors found medium
effect sizes. Small to medium effect sizes were found in
another meta-analysis comparing CBT and pharmaco-
logical interventions [40].
By considering the different effect sizes found in the
cited studies and the insufficient current state of re-
search, we based our sample size calculation on an
expected medium effect size (f = 0.25, α = 0.05, power
80%). The validity and retest reliability of two applied
tests is evaluated in a pilot study and thus is not known
yet. Therefore, we assumed a conservative retest reliability.
For a 2 × 2 multivariate analysis of variance (MANOVA)
the total sample size is set to N = 128.Patient recruitment, randomization and procedure of the
treatment
Participants are recruited via articles in newspapers,
family doctors and gynaecologists, flyers, and different
social networks.
Eligible participants undergo four assessments (see
Figure 1). In the first assessment (t0-assessment), partici-
pants fill out a retrospective screening of premenstrual
symptoms [50] according to the DSM-5 criteria [7]. If
participants fulfil the basic inclusion criteria and primary
DSM-5 criteria (that is, five premenstrual symptoms
including at least one affective symptom), a structured
clinical interview regarding comorbid disorders is con-
ducted via telephone. Afterwards, principally eligible par-
ticipants are invited to complete a daily symptom rating
during two consecutive menstrual cycles, as requested by
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strual (luteal) phases within these two cycles, the partici-
pants fill in the pre-treatment assessment (t1-assessment)
including primary (impairment of premenstrual symptoms)
and secondary outcome measures (coping with premen-
strual symptoms, social support, quality of partnership,
level of stress). If the participants fulfil the diagnostic cri-
teria of a severe PMS or PMDD with regard to the daily
symptom rating, they are randomly assigned to either the
treatment or the wait-list control group. In addition, they
are randomized to one of two psychologists who will be
the responsible psychologist throughout the study.
Participants randomized to the treatment group re-
ceive the Praemensis Programme, a CBT-oriented self-
help treatment lasting 8 weeks. After completion of the
treatment, participants complete the daily symptom
rating and the questionnaires during the luteal phase
(t2-assessment).
Participants assigned to the wait-list have to wait for
8 weeks and do not receive any treatment material. After
the waiting period they complete the symptom diary
and the questionnaires during their luteal phase (t2-
assessment). Subsequently they receive the same treat-
ment and the same post-assessment (t3-assessment). Six
months after the end of the treatment the follow-up
t4-assessment is administered in the luteal phase. It
consists of the same questionnaires as administered at
t1, t2 and t3.
Intervention
The treatment Praemensis Programme is based on CBT
principles. The treatment lasts 8 weeks and its ingredients
are distributed across 14 separate chapters, called mod-
ules. Before starting the treatment, participants receive
detailed instructions on how to use the information, howTable 1 Content of the different modules
Week Content
Cognitive strategies
1 Module 1: Psychoeducation
2 Module C1: Psychoeducation about the role of thoughts and
the relationship to feelings and behaviour (cognitive triad)
3 Module C2: Transfer to PMS-specific context
4 Module C3: Restructuring of dysfunctional cognitions
5 Module C4: Psychoeducation about PMS-specific myths and appli
of learned cognitive strategies
6 Module C5: Psychoeducation about helpful thoughts and develop
of new appraisals
7 Module C6: PMS-specific behaviour (healthcare utilisation, protect
communication)
8 Module 8: Review of the
PMDD, premenstrual dysphoric disorder; PMS, premenstrual syndrome.every module is structured, on the importance of exercises
and on how to deal with technical obstacles.
The treatment starts with an introduction module and
ends with a module about relapse-prevention. The mod-
ules in between are divided into two arms: cognitive
strategies and suggestions for behavioural changes in
lifestyle. For an overview see Table 1. Consequently,
except for the first and the last week, participants work
on two modules in parallel. For these modules, an ap-
proximate working time of 5 hours per week is suggested.
The first module includes psychoeducation about
PMS/PMDD, its aetiology, and treatment. The cognitive
modules provide information about, and strategies for,
identifying and modifying dysfunctional cognitions –
especially PMS-specific cognitions – and PMS-specific
myths and behaviours. The modules including suggestions
for lifestyle changes cover topics such as stress reduction,
sports, and balanced diet. In the last module, a summary
as well as a plan to maintain gains and prevent relapse is
provided. All modules are available for download in pdf
format. They all include practical exercises for applying
and practicing the provided theoretical contents. Add-
itional audio files are provided in order to facilitate
conducting these exercises, such as a tutorial about
progressive muscle relaxation or an audio instruction for
an exercise to collect PMS-associated thoughts.
In addition to written information and audio files, par-
ticipants receive email feedback from a psychologist on a
weekly basis. The psychologists are Master level clinical
psychologists who are at an advanced stage of CBT train-
ing. To ensure therapist adherence to the manual they
receive regular supervision by a licensed CBT therapist.
The modules and audio files, as well as the secured
messaging system to communicate with the clinician, are
delivered via a website.of the module
Behavioural changes in lifestyle
about PMS/PMDD and its aetiology
Module B1: Psychoeducation about the interrelation between
stress and PMS and learning of relaxation techniques
Module B2: Psychoeducation about the interdependency
between alimentation, sport and PMS
Module B3: Integration of sports into daily life by
motivational plans and strategies
cation Module B4: Balanced diet and implementation into daily life
ment Module B5: Psychoeducation about the influence of
stress-related errors in reasoning
ion, Module B6: Training of consumption and implementation
of positive activities into daily life
training and relapse-prevention
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weekly email feedback on the treatment material is
required. If participants do not send their feedback they
receive two email reminders. If they do not reply to
these reminders they are called by their therapist.
Assessments
Clinical primary and secondary outcomes will be assessed
by both self-report questionnaires and clinical interviews.
To ensure compliance with the assessment, participants
receive two reminders via email for every questionnaire
they do not complete. If they do not reply, the interviewer
or the therapist calls the participant.
Diagnostic assessment
Premenstrual symptoms are assessed with two instru-
ments (screening and diary). The German DSM-IV-TR-
based Questionnaire for the Screening of Premenstrual
Symptoms was used for the screening as well as for the
self-development of the diary [50]. It measures the dif-
ferent dimensions of the premenstrual symptoms in a
very detailed way. The questionnaire consists of 27 items
which cover the diagnostic criteria of the DSM-IV-TR
and which is adapted according to the DSM-5. Three
additional items measure the impairment caused by the
checked symptoms (for example, “My social activities
are impaired by these symptoms”). All 30 items are rated
on a four-point rating scale ranging from 0 (not true at
all) to 3 (absolutely true).
These 30 items are assessed first in the retrospective
screening (t0). Here, the items are answered for the lu-
teal and the follicular phase separately. Second, in the
prospective diary, participants rate the 30 items on a
daily basis. A total score as well as a distress index are
calculated. The distress index reflects the intensity of the
symptoms calculated averaged across 5 days.
Demographic variables
The following demographic variables are measured at t0:
age, family status, sexual orientation, citizenship, country
of birth, growing up country (of the participant, her
mother and her father), religion, mother tongue, highest
degree, employment status, height, weight, and number
of births and aborts.
Primary outcome
Impairment caused by premenstrual symptoms The
impairment caused by the premenstrual symptoms is
measured with a self-developed questionnaire called the
Premenstrual Syndrome Impairment Measure (PMS-B),
based on the German Pain Coping Questionnaire [51],
the Pain Disability Index [52] and the Self-Report Mea-
sure for the Assessment of Emotion Regulation Skills
[53]. It is currently being validated in a pilot study. Itconsists of two subscales (mental and functional impair-
ment), with seven items for each. The five-point Likert
scale ranges from 0 (not true at all) to 4 (absolutely
true). Mean values for the subscales as well as for the
whole test are calculated.
Secondary outcome
Coping with premenstrual symptoms Coping with pre-
menstrual symptoms is assessed by a self-developed
questionnaire, the Premenstrual Syndrome Coping
Measure (PMS-C). It is based on the German Pain Cop-
ing Questionnaire [51], the German Version of the
Coping Strategies Questionnaire [54], the Self-Report
Measure for the Assessment of Emotion Regulation
Skills [53], and the Brief COPE [55]. It consists of five
scales with four items each, which are replied to on a
five-point scale ranging from 0 (not true at all) to 4
(absolutely true). Mean values are calculated for the
subscales as well as for the total scale. This question-
naire is also being validated in a pilot study.
Social support The Short-Form Social Support Ques-
tionnaire [56] is employed to measure the availability of
social support. This 22-item measure consists of three
subscales: emotional support, practical support, and so-
cial integration. Four additional items measure satisfac-
tion with the social support and availability of a person
of trust. Each item is rated on a five-point scale ranging
from 1 (not true at all) to 5 (absolutely true). A mean
value for the whole scale is calculated [57]. A moderate
to high reliability has been found in different studies
[57,58]. A good to very good factorial validity has been
demonstrated [57].
Quality of partnership The quality of partnership is
measured with a 25-item measure, the Questionnaire for
the Assessment of Relationship Quality [59]. It consists
of six scales: fascination (three items), engagement for
the relationship (five items), sexuality in the relationship
(five items), perspective of the relationship regarding the
future (five items), mistrust to the partner (three items),
and restriction of the independency (five items). The
single subscales as well as the total score can be inter-
preted. Good psychometric properties have been shown
with Cronbach’s alpha for the subscales ranging between
0.75 and 0.94 [59]. Good to very good convergent valid-
ity was demonstrated (r = 0.59 to 0.84) by two question-
naires measuring partnership quality and partnership
satisfaction and a further questionnaire measuring
depressive mood [59].
Level of stress The Perceived Stress Scale is used to as-
sess the appraisal of situations in life as stressful, particu-
larly as “unpredictable, uncontrollable, and overloaded”
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The items are rated on a five-point scale from 0 (never) to
4 (very often). Good reliability (α = 0.89) as well as good
convergence (r = 0.73) with the State-Trait Anxiety Inven-
tory and good divergent validity (r = 0.02 to 0.18), for
example with the Sensation Seeking Scale, are supported
in a recent study [61].
Statistical analysis
All analyses of the outcomes will be conducted as
intention-to-treat analyses. Between-group changes at post-
treatment on the impairment and the use of coping
strategies will be calculated by using a 2 (pre-treatment/post-
treatment) × 2 (experiment group/waiting list) MANOVA.
Post hoc comparisons will be applied if clarification of
the main effects of the MANOVA is needed. Effect sizes
between the groups will be calculated with Hedges’ g.
Discussion
The current study evaluates an iCBT self-help for PMS,
the Praemensis Programme, and aims to reduce the high
impairment caused by the symptoms and improve the
coping abilities. Benefits and limitations of this approach
are discussed below.
We developed a standardised, manualized intervention
which all participants have to pass through. However,
depending on the severity, the women differ in their
need for treatment and in which modules are appropri-
ate for them [62]. This heterogeneity in treatment-
related needs might be especially relevant in light of the
high variety of PMS-related symptoms [40]. Nevertheless,
to our knowledge, a standardised manualized approach for
treating PMS does not yet exist. Consequently, our pri-
mary aim and the first step is now to evaluate this stan-
dardized and manualized intervention before adapting and
individualising it. Furthermore, individually tailored inter-
ventions are difficult to research in RCTs [40]. A higher
flexibility in selecting the modules should be tested in
further studies. First studies show promising results for a
tailored iCBT [63].
To assess the impairment and coping strategies we de-
veloped two questionnaires. To the best of our knowledge,
German questionnaires which assess the impairment by
and coping with PMS have not yet been developed. Since
we wanted to make sure that we were specifically measur-
ing PMS-related impairment and coping, instead of im-
pairment and coping in general, we decided to use the
newly developed questionnaires.
The careful methodical design of the study allows for a
better understanding of the contradictory findings about
CBT for PMS [39]. First, it is an RCT, whereas many
previous studies did not even include a control group
[64]. Second, we calculate the point of time of the luteal
phase individually for every woman. This procedureenables us to assess the primary and secondary outcome
exactly within the luteal phase. Third, the participants
are diagnosed carefully including a structured clinical
interview for comorbid disorders, a retrospective symp-
tom rating and a symptom diary during two cycles. The
complex diagnostics, in particular the diary (which re-
quires a high motivation), is a particularity of the current
trial. Although the daily symptom rating represents one
of the diagnostic criteria in the DSM-5 [7] it is often
neglected in other studies as well as in clinical routine
[10,40,62]. The new criteria of the DSM-5 have not yet
been proven in practice. Thus, our study might help to
test their practicability.
It has been argued that the diagnosis PMDD can lead
to a pathologization of the menstrual cycle [8,65]. The
programme addresses this problem. First, detailed diag-
nostics help to prevent pathologization [8] by differenti-
ating between women who experience common cycle
changes and women who experience considerable impair-
ment needing treatment [8,62]. Second, the programme is
tailored exclusively to clinically impaired women. Third,
the intervention takes women’s premenstrual experiences
into account without labelling every premenstrual change
as pathologic [66,67] and without labelling the experiences
as fixed categories caused by hormonal or neurotransmit-
ter imbalance [68]. This is realised by considering different
theoretical models (see [38,69,70]) and hence incorporat-
ing the role of social and environmental factors in the psy-
choeducational part as well as when suggesting appraisal
and coping strategies.
The counterpart of a pathologization is to deny pre-
menstrual symptoms [71] which might also be problem-
atic as many women suffering from PMS do not feel
that they are being taken seriously [41,70]. Validation of
their feelings and support for their distress is one of the
most important aspects of a psychological or medical
treatment [41,72]. In our study, the prospective diary
avoids a denial of premenstrual changes by linking the
symptoms clearly to the menstrual cycle. In addition,
within the framework of the intervention, the women
are validated and taken seriously in their feelings and
cognitions.
Future studies should focus on comparing the Praemen-
sis Programme with a different psychological treatment as
a control condition [38]. Technical developments such as
using apps for the diary could be useful and should be
evaluated as well. The implementation of internet-based
interventions in the healthcare system continues to be
difficult; for instance, due to a lack of uptake and engage-
ment [73]. Nevertheless, first attempts at an implementa-
tion are taking place in the United Kingdom [42,73]. If
proven effective, an implementation of the Praemensis
Programme in the healthcare system would be desirable in
the long term and should be pursued.
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ant implications. First, it addresses the problem of in-
sufficient care of women suffering from severe PMS or
PMDD by providing treatment. Second, a careful evalu-
ation of a CBT treatment for PMS will contribute to the
question of whether CBT is promising for the treatment
of PMS/PMDD and might thus shed some light on
contradictory findings regarding the efficacy of CBT for
PMS [39]. Third, it offers treatment for a greater number
of women due to its internet-based design. To our
knowledge, this study is the first study investigating
internet-based therapy for PMS.
Trial status
Participant recruitment began on 1 July 2013 and is still
ongoing.
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